Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
Design, Qualification, and Operation of a Gene Therapy Facility
Michele LevensonSr. Program Manager / Pharmatech Associates, Inc
AIA Quality Assurance
The Building Commissioning Association is a Registered Provider with The American Institute of Architects Continuing Education Systems (AIA/CES). Credit(s) earned on completion of this program will be reported to AIA/CES for AIA members. Certificates of the Completion for both AIA members and non-AIA members are available upon request.
This program is registered with AIA/CES for continuing professional education. As such, it does not include content that may be deemed or construed to be an approval or endorsement by the AIA of any material of construction or any method or manner of handling, using, distributing, or dealing in any material or product.
Questions related to specific materials, methods, and services will be addressed at the conclusion of this presentation.
BCxA Conference – Chicagoland, IL – 2019 2
Learning Objectives
BCxA Annual Conference – Chicagoland, IL – September 2019 3
• Background• Gene Therapy Overview• Design Elements• Qualification on a Mission Critical Project• Good Practices During Routine Operations• Conclusion
Drug Lifecycle
BCxA Annual Conference – Chicagoland, IL – September 2019 4
• Attrition rate is high!
100's of cmpds made
12s of cmpds 2
1 2 3
1Preclinical Evaluation
Phase
1) 20-50 healthy volunteers: Is it safe? What dose is needed?2) 100-500 patient volunteers: Does it work?3) 500-3000 patients: Does it work as well or better than SOC?
Drug Manufacturing Facilities
BCxA Annual Conference – Chicagoland, IL – September 2019 5
* Reference: http://rmcpharmanews.blogspot.com/2012/12/the-cost-of-pharmaceutical-facilities.html
Different Types of Pharma Manufacturing
BCxA Annual Conference – Chicagoland, IL – September 2019 6
Biotech Manufacturing Facility
* Reference: https://cranecpe.com/chem-energy/processmap/biotech-process-map
Tablet Manufacturing Facility
* Reference: http://www.pharmtech.com/role-powder-characterization-continuous-manufacturing
Gene Therapy Overview
BCxA Annual Conference – Chicagoland, IL – September 2019 7
• Viruses introduce their genetic material into cells
• In gene therapy, viral vectors are used to deliver genetic material to cells for a therapeutic effect w/out making patients sick Although created from viruses, viral
vectors are modified so they can no longer self-replicate
Minimizes the risk of handling and no longer considered a virus
• Gene Therapy has the promise of delivering, in as little as a single administration, the missing gene.
Facility Design
BCxA Annual Conference – Chicagoland, IL – September 2019 9
Potential Employee Exposure:
HVAC Design
BCxA Annual Conference – Chicagoland, IL – September 2019 12
• Single pass air• Pressurization schemes• Airlock design and philosophy• Exhaust moved to the roof drives
down risk of cross-contamination• Prevailing wind patterns must still be
demonstrated• Environmental Monitoring program
will have to demonstrate there is no cross-contamination
• Response to containment envelope breach
HVAC Automation and Facility Controls
BCxA Annual Conference – Chicagoland, IL – September 2019 13
• Implementation of sophisticated automation• BMS and/or EMS to handle alarming & remote notifications• Requires a clear plan on how the data will be used:
Quality Metrics Process Validation Stage 3 What kind of data? How will it be monitored? 21 CFR Part 11
• Intelligence associated with these facilities is really high…and, we have the ability to monitor almost every aspect!
HVAC Risk Assessment
BCxA Annual Conference – Chicagoland, IL – September 2019 14
Options System Description Details Cost Delta ($)
Baseline Current Budgeted System
• 10 ton packaged unit and 12,000cfm air handler • 80%Re-Circulated Air/20% Single Pass Outside Air • HEPA filtered Air • No Redundancy
$424,610
0
Option1 100% Single Pass Outside Air
Engineering and Permits Packaged Unit abd Pre-Heater Supply Duct and HEPA Filtration Insulation Exhaust Fan and Duct with Low Wall Registers Controls Zone Heaters (Electric) Air Balance
Total Cost
$ 35,000 $145,000 $155,000 $ 15,000 $ 40,000 $ 70,000 $ 30,000 $ 20,000 $515,000
90,390
Option 2 100% Single Pass Outside Air, 4 Fan Wall Separate Condenser Unit
Engineering and Permits Packaged Unit abd Pre-Heater Supply Duct and HEPA Filtration Insulation Exhaust Fan and Duct with Low Wall Registers Controls Zone Heaters (Electric) Air Balance
Total Cost
$ 35,000 $192,000 $155,000 $ 15,000 $ 40,000 $ 75,000 $ 30,000 $ 20,000 $562,000
137,390
Option2+ 100% Single Pass Outside Air, 100% Air Redundancy, 100% Condenser Redundancy
Engineering and Permits Packaged Unit abd Pre-Heater Supply Duct and HEPA Filtration Insulation Exhaust Fan and Duct with Low Wall Registers Controls Zone Heaters (Electric) Air Balance
Total Cost
$ 35,000 $284,770 $155,000 $ 15,000 $ 45,000 $ 75,000 $ 30,000 $ 20,000 $659,770
235,160
HVAC Risk Assessment, cont’d
BCxA Annual Conference – Chicagoland, IL – September 2019 15
Options System Description Considerations/Risks Technical Regulatory Operating
Baseline Current Budgeted System
• No room isolation • Does not meet FDA or EMA Expectations
• Potential for cross contamination
• Lowest operating cost
Option1 100% Single Pass Outside Air
• Achieves Room Isolation
• No fan redundancy
• Meets FDA and EMA Expectations
• Eliminates potential for cross contamination.
• Higher operating cost because to control temperature of singe pass air
Option 2 100% Single Pass Outside Air, 4 Fan Wall Separate Condenser Unit
• Achieves Room Isolation
• Fan redundancy • Separate Condenser
(low failure risk- 4 compressors)
• Meets FDA and EMA Expectations
• Eliminates potential for cross contamination.
• Higher operating cost than baseline, because to control temperature of singe pass air.
• Slightly higher Qualification costs
• Slightly lower operating cost than Option 1
Option2+ 100% Single Pass Outside Air, 100% Air Redundancy, 100% Condenser Redundancy
• Achieves Room Isolation
• Fan redundancy • Condenser
redundancy
• Meets FDA and EMA Expectations
• Eliminates potential for cross contamination.
• Highest operating cost • Lowest facility
downtime risk • Higher Qualification
Costs
Project Team Dynamics
BCxA Annual Conference – Chicagoland, IL – September 2019 16
Time FLIES when you’re having…a schedule!
The race to production can be even more intense in gene and cellular therapies than it is in ‘emergency’ tech transfer in traditional pharmaceuticals.
Commissioning & Qualification
BCxA Annual Conference – Chicagoland, IL – September 2019 17
• Fast paced project that requires efficiencies!• Specification and Submittal Review• FAT/SAT/AT Review• Commissioning Test Plan finalization and PQ development• Equipment relocation (where applicable)• Portable and COTS equipment• CTP and PQ (where applicable) Execution
Classical Validation Paradigm
BCxA Annual Conference – Chicagoland, IL – September 2019 18
User Requirements (URS)
Functional Requirements
(FRS)
Design Specifications(DS)
Commissioning
Installation Qualification (IQ)
Operational Qualif ication
(OQ)
Performance Qualif ication
(PQ)Verifies
Verifies
Verifies
Validation V Model
Risk Based Validation
BCxA Annual Conference – Chicagoland, IL – September 2019 19
• Approach to validation based on risk factor of the functions of the system or equipment
• The goal is to determine the impact, likelihood, and detectability of a failure to establish the overall risk of each scenario
• Risk is assessed using system impact assessment where each function requirement of the system is weighted and tested as appropriate
• Classic validation would test each functional requirement of the system equally
HVAC & Isolator/BSCs PQs
BCxA Annual Conference – Chicagoland, IL – September 2019 21
• Coordination of EM sampling requires close communication between the various groups.
• Maximum room capacities influence the level of room cleanliness.
• Specific sampling points on risk-based qualification.• Operations should be simulated per current procedures during
dynamic testing.• Sequence of cleanings/equipment hold times, static and
dynamic sampling must be planned ahead of time.
HVAC Commissioning versus IOQ and PQ
BCxA Annual Conference – Chicagoland, IL – September 2019 22
Commissioning Installation & Operational Qualification Performance Qualification
AHUs and associated EF’s tested
Room particle tested
Balancing/ACPH data review
Smoke Testing, etc.
System functionality & system features are tested
* Pre-requisite: Commissioning
Baseline data collection for Environmental Monitoring (EM) program.
Rooms tested typically under static & dynamic conditions
* Pre-requisite: IOQ, facility GMP cleaning
Allogenic versus Autologous Manufacturing
BCxA Annual Conference – Chicagoland, IL – September 2019 23
One to a bigger one One to many ones
Qualifying equipment for a scaled-up process can be more challenging than for one that has been scaled out
vs.
Segregation
BCxA Annual Conference – Chicagoland, IL – September 2019 25
• Biggest concern – the risk of cross contamination!
• Training for the operators – aseptic gowning, aseptic techniques
HVAC Stability Strategy
BCxA Annual Conference – Chicagoland, IL – September 2019 26
• Must be able to demonstrate that all controlled areas (classified and unclassified) for temperature, humidity and pressure must remain in a state of control
• Emergency generators must back up all critical operations within the suite
• General operations (offices, canteen, etc.,) can go on energy savings or be turned off during non-use hours.
Conclusions
BCxA Annual Conference – Chicagoland, IL – September 2019 27
• Segregation of each step of the manufacturing process is key to prevent cross-contamination. Virus particles are on the nanometer scale and can easily pass through a 0.1 micron
“sterile barrier” filter, posing a high risk for environmental contamination.
• Best way to avoid the common failure points build them into the design and reviewed by a cross-functional team.
• Must understand how the facility and equipment will be used to successfully qualify and operate the facility.